Search tips
Search criteria 


Logo of oncotargetLink to Publisher's site
Oncotarget. 2016 November 22; 7(47): 77807–77814.
Published online 2016 October 21. doi:  10.18632/oncotarget.12799
PMCID: PMC5363622

Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI


Diagnosis of cardiac sarcoidosis is often challenging. Whereas cardiac magnetic resonance imaging (CMR) and positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) are most commonly used to evaluate patients, PET/CT using radiolabeled somatostatin receptor (SSTR) ligands for visualization of inflammation might represent a more specific alternative. This study aimed to investigate the feasibility of SSTR–PET/CT for detecting cardiac sarcoidosis in comparison to CMR.

15 patients (6 males, 9 females) with sarcoidosis and suspicion on cardiac involvement underwent SSTR-PET/CT imaging and CMR. Images were visually scored. The AHA 17-segment model of the left myocardium was used for localization and comparison of inflamed myocardium for both imaging modalities. In semi-quantitative analysis, mean (SUVmean) and maximum standardized uptake values (SUVmax) of affected myocardium were calculated and compared with both remote myocardium and left ventricular (LV) cavity.

SSTR-PET was positive in 7/15, CMR in 10/15 patients. Of the 3 CMR+/PET subjects, one patient with minor involvement (<25% of wall thickness in CMR) was missed by PET. The remaining two CMR+/PET patients displayed no adverse cardiac events during follow-up.

In the 17-segment model, PET/CT yielded 27 and CMR 29 positive segments. Overall concordance of the 2 modalities was 96.1% (245/255 segments analyzed). SUVmean and SUVmax in inflamed areas were 2.0±1.2 and 2.6±1.2, respectively. The lesion-to-remote myocardium and lesion-to-LV cavity ratios were 1.8±0.2 and 1.9±0.2 for SUVmean and 2.0±0.3 and 1.7±0.3 for SUVmax, respectively.

Detection of cardiac sarcoidosis by SSTR-PET/CT is feasible. Our data warrant further analysis in larger prospective series.

Keywords: sarcoidosis, DOTATOC, SSTR, somatostatin receptor, PET


Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can virtually involve all organ systems [1]. Whereas lymph nodes and lungs are most commonly affected, cardiac involvement is present in up to one third of patients [2, 3] and has been reported as the second leading cause of death by sarcoidosis in the United States and the leading cause in Japan [4]. Therefore, early diagnosis and treatment initiation is mandatory. However, diagnosis is often challenging due to the patchy, multifocal pattern of the disease rendering sensitivity of endomyocardial biopsy as low as 20-30% [5]. In clinical routine, the Guidelines of the Japanese Ministry of Health and Welfare (JMHWG) and the Heart Rhythm Society (HRS) serve as a standard for the diagnosis of cardiac sarcoidosis (CS) and include a combination of clinical and imaging findings, such as ECG abnormalities and signs of acute myocardial damage on established cardiac imaging techniques [6, 7]. In terms of cardiac imaging, both cardiac magnetic resonance imaging (CMR) and positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) have proven its value for CS detection and patient prognostication [2, 810]. However, specificity of FDG-PET is hampered by physiologic tracer accumulation requiring dedicated patient preparation [1113]. As a more specific alternative, feasibility of PET targeting the somatostatin receptor (SSTR) subtype 2 has been demonstrated for imaging atherosclerosis [1416], myocardial inflammation [17] and CS [18]. The aim of this study was to further assess the feasibility of SSTR–PET/CT for detecting CS in comparison to CMR.


Clinical findings

All but one patient (Patient #9) presented with biopsy-proven sarcoidosis. Most commonly, mediastinal und hilar lymph nodes (n=13) and the lungs (n=14) were affected. Other sites of organ involvement included spleen (n=2), liver (n=2), skin (n=2), bone (n=1), parotic glands (n=1), omentum (n=1), uvea (n=1) and the nasal sinuses (n=1).

Cardiac involvement was suspected due to (a mixture of) typical clinical symptoms such as frequent palpitations and/or supra- and ventricular premature beats in long-term holter monitoring (n=6), aberrant rest ECG findings including bifascicular blocks (n=5), ventricular tachycardia (n=2), severe or otherwise unexplainable heart failure (n=5) or shortness of breath (n=3). Two patients initially presented with both acute chest pain and elevated cardiac enzymes. Coronary artery disease was excluded in these patients invasively. Two patients had biopsy-proven cardiac involvement and were referred for follow-up examinations.

At the time of imaging, 11/15 patients were treatment-naïve. Patient #5 presented with corticosteroids and azathioprine due to extensive pulmonary involvement, patients #6, #11, and #14 were treated with prednisolone. During follow-up, four patients developed severe ventricular tachycardia that required the implantation of an ICD (n=2) or protection by a life vest (n=2). All other patients had no cardiac events. However, six subjects were started on immunosuppressive therapy (after imaging).

A concise overview of patients′ characteristics can be found in Table Table11.

Table 1
Patients' characteristics

Imaging results

On visual inspection, SSTR-PET/CT returned positive findings in 7/15, CMR in 10/15 patients. Of the 3 CMR+/PET subjects, one patient (patient #3) with minor involvement (<25% of wall thickness in CMR) was missed by PET, most likely due to partial volume effects and the rather modest intensity of the tracer signal. The remaining two CMR+/PET patients (patients #11 and #14) displayed no adverse cardiac events during follow-up, and repeated CMR imaging revealed stable morphologic myocardial changes. In total, both modalities returned concordant results in 12/15 subjects.

In a total of 255 segments analyzed, there were 27 segments positive in 68Ga-DOTA-TOC-PET/CT and 29 segments positive in CMR, respectively. Overall, retention of the radiotracer 68Ga-DOTA-TOC was rated mild or moderate and no segment was rated intense (mild retention in 11/27 (41%) segments; moderate retention, 16/27; 59%). Typical PET-findings illustrating enhanced tracer uptake in both a patient with extensive (patient #8) as well as a subject without cardiac involvement (patient #6; positive mediastinal lymph nodes present) are given in Figure Figure11 and Figure Figure2,2, respectively.

Figure 1
Display of a patient with active myocardial sarcoidosis
Figure 2
Display of a patient without myocardial sarcoidosis

On a head-to-head comparison, SSTR-PET and CMR were concordantly positive in 23 segments (23/29 segments positive at CMR; 79.3%). 4 segments were SSTR-PET positive and MRI-negative (1.6%; 4/255), 6 SSTR-PET negative and MRI-positive (2.4%; 6/255). Both modalities returned negative results in 222 segments, thus leading to an overall concordance of 96.1% (Table (Table2).2). The individual results of the 17-segment analysis for both sub-groups can be inferred from Supplementary Figure S1.

Table 2
Concordance of cardiac MRI and somatostatin-receptor- (SSTR-) based PET/CT in patients with suspected cardiac sarcoidosis

Semi-quantitative analysis

SUVmean and SUVmax were significantly higher in the inflamed myocardium as compared to remote myocardium or the left ventricular (LV) cavity. SUVmean in inflamed areas ranged from 1.3-4.5 (mean, 2.0±1.2) and SUVmax from 1.4-5.0 (mean, 2.6±1.2), respectively. The SUVmean ratios of lesion-to-remote myocardium were 1.8±0.2 and for lesion-to-LV cavity 1.9±0.2. The corresponding SUVmax ratios were 2.0±0.3 and 1.7±0.3, respectively.


To our knowledge, this is the first study to assess the performance of SSTR-directed PET/CT in comparison to CMR in cardiac sarcoidosis. General feasibility of somatostatin receptor targeted imaging of inflammatory cells in sarcoidosis by means of 111In-labeled pentetreotide had already been demonstrated in the late 90s [19, 20]. Our group previously reported on the suitability of SSTR-PET/CT in a single patient with septal involvement of sarcoidosis [18]. In this two-center study, we were able to confirm previous results. SSTR-PET/CT identified myocardial uptake consistent with inflammatory activity of sarcoid granulomas in 7/15 patients, thereby demonstrating high concordance with CMR. Distribution of the radiotracer matched with CMR late-gadolinium-enhancement and T2-weighted edema, demonstrating focal accumulation within areas of myocardial inflammation in 23 of 29 involved segments (79%).

On a patient basis, one patient with minor involvement (<25% of wall thickness in CMR) was missed, most likely due to partial volume effects and the rather modest intensity of the tracer signal. The remaining two CMR+/PET- patients displayed no adverse cardiac events during follow-up. Of note, repeated CMR imaging revealed stable morphologic myocardial changes consistent with chronic post-inflammatory processes.

Though tracer uptake in damaged myocardium was almost twice as high as compared to the background of the left ventricular cavity or remote unaffected myocardium, SUVmax of sarcoid lesions ranged between 1.4 and 5.0 and were therefore much lower than those reported for 18F-FDG [21, 22]. However, since the myocardium does not display any physiologic 68Ga-DOTATOC uptake, tracer retention in the heart can be considered specific. Interestingly, in one patient in whom both 18F-FDG- and 68Ga-DOTATOC-PET were available in addition to CMR (patient #10), 18F-FDG failed to detect active inflammation whereas both SSTR-PET and CMR returned findings highly consistent with sarcoidosis. Clinically, the patient developed ventricular tachyarrhythmia the day after CMR.

As another advantage, SSTR-directed imaging obviates the need to adhere to specific patient preparation protocols including prolonged fasting, ingestion of low-carbohydrate, high-fat meals or the injection of heparin prior to radiotracer injection [12, 13, 23].

Up to now, only few studies have addressed the value of SSTR-PET/CT for the imaging of cardiovascular inflammation with most reports focusing on the detection of atherosclerosis [1416].

In its translation to cardiac sarcoidosis, this approach might allow for direct assessment of disease activity, especially in the course of treatment. While the current gold standard MRI depicts structural changes like cardiac damage and scarring and edema with the highest spatial resolution, 68Ga-DOTATOC uptake may directly reflect the underlying immunological cell activity. In future, given the complementary nature of PET and MRI signals, the combination of the two may be the optimal diagnostic approach, preferably by integrated MRI/PET.

Additionally, whereas a recent study comparing 68Ga-DOTANOC and 18F-FDG PET/CT has demonstrated encouraging diagnostic accuracy for SSTR-directed PET [24], the prognostic value of 68Ga-DOTATOC PET/CT, especially in comparison to 18F-FDG has to be clarified in future trials. Whereas higher quantitative 18F-FDG uptake in CS patients with ventricular tachycardia than in those with atrioventricular block and asymptomatic controls and a higher risk of death or ventricular tachycardia as compared to JMHWG criteria or the ejection fraction have been reported for 18F-FDG [9, 25], nothing is known about patient prognostication by SSTR-PET/CT so far. Interestingly, one patient with extensive cardiac involvement (patient #6) experienced sudden malignant ventricular tachycardia with subsequent cardiogenic shock requiring mechanical circulatory support. Although no conclusions can be drawn from a single example in this patient cohort, the extent of SSTR-PET+ myocardial areas might provide the same prognostic information as shown for 18F-FDG-PET/CT, given that somatostatin receptor-directed PET directly targets the underlying inflammatory cells.

Our work has several limitations. Most importantly, histopathologic proof of sarcoid granulomas and SSTR expression as the adequate reference test was not available. Cardiac gating for PET imaging was not performed. Early contrast enhancement CMR studies were not included. Data on short-term reproducibility of our findings are missing and should be the subject of subsequent work.

In conclusion, imaging of cardiac sarcoidosis using SSTR-targeted PET/CT is feasible. Our pilot data warrant further analysis in a larger prospective series.


Subjects and study design

A total of 15 patients (6 males and 9 females, median age, 52 years: range, 22-80 years) with histologically proven sarcoidosis (14/15) and the clinical suspicion of cardiac involvement underwent both SSTR-PET/CT as well as CMR on a compassionate use base at the German University Centers of Bonn and Würzburg. No patient had a current or prior history of cardiac disease (e.g. prior infarction, myocarditis or cardiomyopathy). Imaging was performed within a median of 27 days (range, 1-57 days).

German federal laws accept the use of the radiotracer 68Ga-DOTA-TOC under conditions of the pharmaceutical law. Written informed consent was obtained prior to the study from all patients.

Preparation of 68Ga-DOTATOC

In Würzburg, 68Ga–DOTATOC was prepared using a modification of the method described previously by Breeman et al. [26] using a SCINTOMICS module (Scintomics, Fürstenfeldbruck, Germany). The synthesis was carried out on a computer-assisted synthesis module (Scintomics, Fürstenfeldbruck, Germany). The labeling procedure was optimized concerning amount of peptide, reaction time and reaction temperature. Radiochemical purity was determined by gradient HPLC (Scintomics, Fürstenfeldbruck, Germany).

In Bonn, an improved manual method developed by Eppard and colleagues was used [27].

PET imaging

PET scans were acquired using an integrated PET/CT scanner (Siemens Biograph 2 [Bonn], Siemens Biograph mCT 64 [Würzburg], Siemens, Knoxville, USA) consisting of a LSO full-ring PET and a 2 or 64-slice spiral CT. 124±31 MBq of 68Ga-DOTA-TOC were injected. After a period of 60 min, transmission data were acquired using low-dose CT of the thorax (16 mAs, 130 kV, 512 × 5215 matrix, 5 mm slice thickness, increment of 15 mm/s, rotation time of 0.8 s, and pitch index of 1.2 [Bonn], 80 mAs, 120 kV, 512 × 512 matrix, 5mm slice thickness, increment of 30 mm/s, rotation time of 0.5s, and pitch index of 0.8 [Würzburg]). Consecutively, PET emission data of the heart were acquired in three-dimensional mode over 10 minutes. PET data were reconstructed into a 128 × 128 [Bonn] or 200 × 200 [Würzburg] matrix using the iterative algorithm implemented by the manufacturer including decay and scatter correction based on the acquired CT data.

Images were first inspected visually by two experienced nuclear medicine physicians (CL and AKB; RAB and FCG, respectively). For quantification of increased tracer uptake, a visual score using the terms “mild”, “moderate” and “intense” was used. Areas of increased 68Ga-DOTATOC accumulation were documented using the 17-segment AHA heart model [28].

For semi-quantitative analysis, the axial PET image slice with maximum cardiac uptake was selected. A standardized 15mm circular region was placed over the area with the peak activity. This first ROI was used to derive maximum (SUVmax) and mean standardized uptake values (SUVmean). SUVmax and SUVmean were also derived in normal reference regions defined by two distinct methods: (1) a second ROI (diameter of 15 mm) in a remote region of the left ventricular wall (not supplied by the culprit vessel) without late-gadolinium-enhancement (LGE) in the corresponding MRI data (if applicable) and (2) another ROI with a diameter of 25 mm in the left ventricular cavity. Signal-to-background ratios were calculated for each method.

CMR imaging

CMR was performed on a 1.5 T (n=12, Achieva 1.5T, Philips Healthcare, Best, The Netherlands) and 3.0T (n=3, Achieva DS 3.0T, Philips Healthcare, Best, The Netherlands) scanner using dedicated phased array coil for radiofrequency reception. Sequences were gated to the heart cycle via a four lead vector cardiogram. The protocol included a morphologic study based on balanced turbo field echo sequences for documentation of standard cine long and short axis views (FOV 380 mm, flip angle 60°, TE 2.6 – 3.0 ms, TR 130-158 ms). A T2-weighted multi echo gradient echo sequence was used for imaging myocardial edema in both long and short axis (FOV 370 ms, NSA 2, TE 90 ms, TR 2000 -3600 ms, TR (beats) 3). Late enhancement imaging was performed 9 to 12 min after antecubital intravenous administration of 0.15 mmol/kg of a gadolinium based contrast agent (Gadobutrol, Bayer HealthCare, Leverkusen, Germany). An inversion recovery T1 turbo field echo sequence was used, and the inversion time was adjusted to completely null the myocardial signal.

Image analysis was performed using the Extended Workspace software (EWS, Philips Healthcare, Best, The Netherlands). In analogy to PET, all LGE and T2-weighted scans were segmentally analyzed with regards to scar and edema distribution within the myocardium according to the 17-segment model. Concordant signal enhancement in both LGE and T2-weighted sequences was considered as CMR positive for active cardiac involvement. LGE positivity in parallel with T2 negativity was rated as consistent with fibrotic changes.

Statistical analysis

Most data presented in here are descriptive. Quantitative data are presented as median, range, and mean ± SD.




All authors declare no conflicts of interest.


1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, et al. Clinical characteristics of patients in a case control study of sarcoidosis. American journal of respiratory and critical care medicine. 2001;164:1885–1889. [PubMed]
2. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–1977. [PMC free article] [PubMed]
3. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, Machac J, Teirstein A. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–1435. [PubMed]
4. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. The American journal of medicine. 1996;100:423–427. [PubMed]
5. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. European heart journal. 2007;28:3076–3093. [PubMed]
6. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. Journal of cardiovascular electrophysiology. 2009;20:578–583. [PubMed]
7. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart rhythm. 2014;11:1305–1323. [PubMed]
8. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, Yoshikawa J. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. Journal of nuclear medicine. 2003;44:1030–1036. [PubMed]
9. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. Journal of the American College of Cardiology. 2014;63:329–336. [PMC free article] [PubMed]
10. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, Gulenchyn KY, Dekemp RA, Dasilva J, Birnie D, Wells GA, Beanlands RS. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. Journal of nuclear medicine. 2012;53:241–248. [PubMed]
11. Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe M. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity. Clinical nuclear medicine. 2013;38:128–130. [PubMed]
12. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926–936. [PubMed]
13. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR American journal of roentgenology. 2008;190:W151–156. [PubMed]
14. Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, Bauer W. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI research. 2012;2:52. [PMC free article] [PubMed]
15. Li X, Bauer W, Kreissl MC, Weirather J, Bauer E, Israel I, Richter D, Riehl G, Buck A, Samnick S. Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis. 2013;230:33–39. [PubMed]
16. Schatka I, Wollenweber T, Haense C, Brunz F, Gratz KF, Bengel FM. Peptide receptor-targeted radionuclide therapy alters inflammation in atherosclerotic plaques. Journal of the American College of Cardiology. 2013;62:2344–2345. [PubMed]
17. Lapa C, Reiter T, Li X, Werner RA, Samnick S, Jahns R, Buck AK, Ertl G, Bauer WR. Imaging of myocardial inflammation with somatostatin receptor based PET/CT - A comparison to cardiac MRI. International journal of cardiology. 2015;194:44–49. [PubMed]
18. Reiter T, Werner RA, Bauer WR, Lapa C. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. European heart journal. 2015;36:2404. [PubMed]
19. Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WAP, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284–1292. [PubMed]
20. Lebtahi R, Crestani B, Belmatoug N, Daou D, Delahaye N, Dombret MC, Faraggi M, Aubier M, Le Guludec D. Somatostatin receptor scintigraphy in patients with sarcoidosis: Comparison with gallium-67 scintigraphy. Journal of Nuclear Medicine. 1998;39:44p–44p.
21. Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A, Higaki J, Mochizuki T. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. International journal of cardiology. 2015;195:180–187. [PubMed]
22. Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, Govender P, Ruberg FL, Miller EJ. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal of nuclear cardiology. 2014;21:925–939. [PubMed]
23. Kaneta T, Hakamatsuka T, Takanami K, Yamada T, Takase K, Sato A, Higano S, Kinomura S, Fukuda H, Takahashi S, Yamada S. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med. 2006;20:203–208. [PubMed]
24. Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI research. 2016;6:52. [PMC free article] [PubMed]
25. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, DaSilva J, Wells GA, Beanlands RS, Nery PB. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by (1)(8)F- fluorodoexyglucose positron emission tomography? Circulation Cardiovascular imaging. 2013;6:617–626. [PubMed]
26. Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Seminars in nuclear medicine. 2011;41:314–321. [PubMed]
27. Eppard E, Perez-Malo M, Rösch F. Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol. EJNMMI Radiopharmacy and Chemistry. 2016.
28. Imaging guidelines for nuclear cardiology procedures, part 2. American Society of Nuclear Cardiology. Journal of nuclear cardiology. 1999;6:G47–84. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC